Yubo International Biotech LTD

Yubo International Biotech Limited announced a change in its independent registered public accounting firm, with HHL LLP resigning and HCL, PLLC being appointed, following HHL's prior 'going concern' explanatory paragraph.

Yubo International Biotech Limited has entered into a securities purchase agreement to issue 50.6 million Class A Common Shares to its President and CEO, converting $2.53 million in shareholder loans into equity at a premium to market price.

Yubo International Biotech replaces its independent registered public accounting firm due to the retirement of Michael T. Studer, engaging HHL LLP as the new auditor.

Yubo International Biotech has changed its independent registered public accounting firm from Michael T. Studer CPA P.C. to HHL Advisors Group, effective January 2, 2025, due to the retirement of Mr. Studer.

Yubo International Biotech reported zero revenue and a net loss of $295,026 for the first quarter of 2026, citing ongoing market research and evaluation.

Yubo International Biotech Limited reported zero revenue for the nine months ended September 30, 2025, alongside a significant net loss and a going concern warning.

Yubo International Biotech Limited reported no sales for the first half of 2025, alongside continued significant net losses and a going concern warning.

Yubo International Biotech reports zero revenue for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Yubo International Biotech's Q3 2024 results show a significant decrease in revenue and an increase in operating expenses, leading to a net loss.

Yubo International Biotech's Q2 2024 results reveal a significant decrease in revenue and increased operating expenses, leading to a larger net loss compared to the same period last year.

Yubo International Biotech Limited files its Form 10-K, reporting financial results for the fiscal year ended December 31, 2024, highlighting a net loss and discussing risks associated with its VIE structure and operations in China.

Yubo International Biotech Limited's 2023 annual report details increased revenue driven by new health management services, alongside ongoing development of its endometrial stem cell bank.

Yubo International Biotech Ltd's President and 10% owner, Jun Wang, acquired 42 million Class A Common Stock shares at $0.05 each by converting company debt into equity.

Yubo International Biotech Ltd's CEO, Wang Yang, acquired 8.6 million Class A Common Stock shares at $0.05 each by converting $430,000 of company debt into equity.

Boao Biotech Ltd, a significant shareholder and director of Yubo International Biotech Ltd, has sold over 5 million shares of Class A Common Stock for $0.30 per share.

Yubo International Biotech Ltd.'s CEO, Director, and 10% owner, Wang Yang, has sold 2 million shares of Class A Common Stock for $0.12 per share, reducing his beneficial ownership.

Yubo International Biotech Limited informs stockholders of actions taken by written consent, including the election of directors, ratification of the auditor, and issuance of shares to settle shareholder loans.

Yubo International Biotech Limited converted $2.53 million in debt owed to its beneficial owners into 50.6 million Class A Common Stock shares, increasing Chinaone Technology Limited's beneficial ownership to 15.1%.

Flydragon International Ltd and its controlling person, Jun Wang, significantly increased their beneficial ownership in Yubo International Biotech Limited to 48.1% through a private placement that converted company debt into equity.

Chinaone Technology Limited and its controlling person, Yang Wang, have significantly reduced their beneficial ownership in Yubo International Biotech Ltd by selling 2 million shares of Class A Common Stock.

Boao Biotech Ltd and its sole director, Yulin Cao, have jointly disclosed a beneficial ownership of 16.6% of Yubo International Biotech Ltd's Class A Common Stock.